Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. (Q38682317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

meta-analysis

0 references

title

Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

1 reference

type 2 diabetes

9 December 2023

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Aris Liakos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Thomas Karagiannis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Apostolos Tsapas

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Chrysoula Rizava

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Eleni Athanasiadou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Konstantinos Papatheodorou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Maria Mainou

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Maria Rika

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Panagiota Boura

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

29 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

458-480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12020-015-0841-1

3 March 2020

exact match

0 references

cites work

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Demonstrating the burden of hypoglycemia on patients' quality of life in diabetes clinical trials: measurement considerations for hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Effect of vildagliptin as add-on therapy to a low-dose metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Effect of vildagliptin on hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0841-1

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

21 January 2018

1 reference

12 December 2020

A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus

1 reference

12 December 2020

Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

1 reference

12 December 2020

Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

1 reference

12 December 2020

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

12 December 2020

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study

1 reference

12 December 2020

Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus

1 reference

12 December 2020

A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study

1 reference

12 December 2020

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

1 reference

12 December 2020

10.1007/S12020-015-0841-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26714458%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference